With increasing time pressures to move biological therapeutics into the clinic, bioprocessing development studies have to be limited. Currently, core studies typically involve the use of shake flasks and benchtop bioreactors to select the most productive clones, optimum media, and bioprocessing conditions. The capacity for using benchtop bioreactors is especially limited as it is resource-intensive and has high capital equipment and infrastructure costs. Consequently, scientists frequently cannot perform full design-of-experiments (DoE) and are generally only able to take one or two of their most promising clones forward for partial DoE runs in benchtop bioreactors.